TGFbeta1	0	8	B-Gene_or_gene_product
,	8	9	O
back	10	14	O
to	15	17	O
the	18	21	O
future	22	28	O
:	28	29	O
revisiting	30	40	O
its	41	44	O
role	45	49	O
as	50	52	O
a	53	54	O
transforming	55	67	O
growth	68	74	O
factor	75	81	O
.	81	82	O

TGFbeta1	84	92	B-Gene_or_gene_product
was	93	96	O
initially	97	106	O
identified	107	117	O
in	118	120	O
culture	121	128	O
media	129	134	O
from	135	139	O
transformed	140	151	B-Cell
cells	152	157	I-Cell
as	158	160	O
part	161	165	O
of	166	168	O
a	169	170	O
factor	171	177	O
that	178	182	O
could	183	188	O
produce	189	196	O
a	197	198	O
transformed	199	210	O
phenotype	211	220	O
in	221	223	O
a	224	225	O
nontransformed	226	240	B-Cell
cell	241	245	I-Cell
line	246	250	O
.	250	251	O

Subsequently	252	264	O
this	265	269	O
activity	270	278	O
was	279	282	O
separated	283	292	O
into	293	297	O
TGFbeta	298	305	B-Gene_or_gene_product
and	306	309	O
TGFalpha	310	318	B-Gene_or_gene_product
an	319	321	O
EGF	322	325	B-Gene_or_gene_product
receptor	326	334	O
ligand	335	341	O
.	341	342	O

With	343	347	O
the	348	351	O
discovery	352	361	O
that	362	366	O
TGFbeta1	367	375	B-Gene_or_gene_product
was	376	379	O
a	380	381	O
potent	382	388	O
growth	389	395	O
inhibitor	396	405	O
of	406	408	O
epithelial	409	419	B-Cell
cells	420	425	I-Cell
,	425	426	O
and	427	430	O
the	431	434	O
identification	435	449	O
of	450	452	O
inactivating	453	465	O
mutations	466	475	O
within	476	482	O
the	483	486	O
TGFbeta1	487	495	B-Gene_or_gene_product
signaling	496	505	O
pathway	506	513	O
in	514	516	O
cancers	517	524	B-Pathological_formation
it	525	527	O
became	528	534	O
clear	535	540	O
that	541	545	O
TGFbeta1	546	554	B-Gene_or_gene_product
signaling	555	564	O
is	565	567	O
a	568	569	O
tumor	570	575	B-Pathological_formation
suppressor	576	586	O
pathway	587	594	O
for	595	598	O
early	599	604	O
stages	605	611	O
of	612	614	O
cancer	615	621	B-Pathological_formation
.	621	622	O

However	623	630	O
many	631	635	O
human	636	641	B-Organism
carcinomas	642	652	B-Pathological_formation
overexpress	653	664	O
TGFbeta1	665	673	B-Gene_or_gene_product
and	674	677	O
this	678	682	O
is	683	685	O
associated	686	696	O
with	697	701	O
poor	702	706	O
patient	707	714	B-Organism
prognosis	715	724	O
and	725	728	O
increased	729	738	O
frequency	739	748	O
of	749	751	O
metastasis	752	762	O
.	762	763	O

Similar	764	771	O
results	772	779	O
have	780	784	O
been	785	789	O
obtained	790	798	O
with	799	803	O
tumor	804	809	B-Cell
cell	810	814	I-Cell
lines	815	820	I-Cell
and	821	824	O
experimental	825	837	O
animal	838	844	O
models	845	851	O
.	851	852	O

Thus	853	857	O
stage	858	863	O
specific	864	872	O
duality	873	880	O
of	881	883	O
function	884	892	O
is	893	895	O
the	896	899	O
emerging	900	908	O
paradigm	909	917	O
for	918	921	O
the	922	925	O
role	926	930	O
of	931	933	O
TGFbeta1	934	942	B-Gene_or_gene_product
in	943	945	O
cancer	946	952	B-Pathological_formation
.	952	953	O

This	954	958	O
review	959	965	O
will	966	970	O
focus	971	976	O
on	977	979	O
the	980	983	O
evidence	984	992	O
for	993	996	O
TGFbeta1	997	1005	B-Gene_or_gene_product
as	1006	1008	O
a	1009	1010	O
tumor	1011	1016	B-Pathological_formation
promoting	1017	1026	O
and	1027	1030	O
metastasis	1031	1041	O
factor	1042	1048	O
and	1049	1052	O
examine	1053	1060	O
the	1061	1064	O
biological	1065	1075	O
and	1076	1079	O
molecular	1080	1089	O
basis	1090	1095	O
for	1096	1099	O
these	1100	1105	O
effects	1106	1113	O
.	1113	1114	O

It	1115	1117	O
is	1118	1120	O
proposed	1121	1129	O
that	1130	1134	O
the	1135	1138	O
switch	1139	1145	O
from	1146	1150	O
tumor	1151	1156	B-Pathological_formation
suppressor	1157	1167	O
to	1168	1170	O
oncogene	1171	1179	O
reflects	1180	1188	O
genetic	1189	1196	O
or	1197	1199	O
epigenetic	1200	1210	O
alterations	1211	1222	O
in	1223	1225	O
signaling	1226	1235	O
pathways	1236	1244	O
in	1245	1247	O
tumor	1248	1253	B-Cell
cells	1254	1259	I-Cell
that	1260	1264	O
alter	1265	1270	O
the	1271	1274	O
readout	1275	1282	O
from	1283	1287	O
the	1288	1291	O
TGFbeta1	1292	1300	B-Gene_or_gene_product
pathway	1301	1308	O
.	1308	1309	O

